Daxor Corp (DXR) Stock Price, Quote & News

Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Website: www.daxor.com

Address:

109 Meco Lane, Oak Ridge, United States

akts Apr. 16 at 2:04 AM

$DXR This is about the most poorly 'marketed' companies I have seen. Their equity holdings alone are worth $7/share. Their operational business is supported by the dividends, but that's a free option for the shareholder. Could be a while before this stock/company starts to move. A true sleeper in every way.

0 · Reply

theshortsqueezer2022 Apr. 15 at 12:05 PM

$DXR never moves with news. 🤦🏻‍♂️ New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival https://www.stocktitan.net/news/ENSC/ensysce-biosciences-announces-positive-data-from-opioid-overdose-69ir17v7mbhe.html

0 · Reply

CEOBuysDisclosures Apr. 7 at 9:25 PM

$DXR CEO purchased 2,063 shares at $7.89 for a total of $16,277. Feldschuh Michael Richard now owns 212,694 shares. https://ceo-buys.com

0 · Reply

DonCorleone77 Mar. 28 at 12:09 PM

$DXR Daxor expands blood volume analysis technology across three networks Daxor announces a significant expansion into three regional healthcare facilities across the U.S. Recent sales wins include: A Midwest academic medical center has integrated Daxor's BVA technology to enhance outpatient cardiovascular care; a Wisconsin primary health center has deployed Daxor's BVA solution to improve outpatient syncope assessment and treatment; A cardiovascular care program in Southern New Jersey has adopted Daxor's BVA technology across inpatient and outpatient setting.

1 · Reply

NVDAMillionaire Mar. 22 at 6:57 PM

$DXR Digging the blood volume tech. Potential game-changer for medical diagnostics. Watching closely for FDA approval on next-gen analyzer. thoughtful article: https://beyondspx.com/article/daxor-corporation-dxr-revolutionizing-patient-care-through-innovative-blood-volume-analysis

0 · Reply

CEOBuysDisclosures Mar. 20 at 11:15 PM

$DXR CEO purchased 1,492 shares at $7.72 for a total of $11,518. Feldschuh Michael Richard now owns 208,984 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures Mar. 20 at 11:10 PM

$DXR CEO purchased 647 shares at $8.15 for a total of $5,273. Feldschuh Michael Richard now owns 209,631 shares. https://ceo-buys.com

0 · Reply

JarvisFlow Mar. 17 at 11:00 AM

Ascendiant Capital has adjusted their stance on Daxor ( $DXR ), setting the rating to Buy with a target price of 24.75 → 25.

0 · Reply

CEOBuysDisclosures Mar. 11 at 3:40 PM

$DXR CEO purchased 3,360 shares at $7.68 for a total of $25,805. Feldschuh Michael Richard now owns 210,852 shares. https://ceo-buys.com

0 · Reply

topstockalerts Feb. 26 at 12:36 PM

Pre Market Top Gainers PT2 $HCTI $SMCX $AC $DXR $PRCH

0 · Reply

Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

May 13, 2025, 8:00 AM EDT - 6 weeks ago

Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

May 7, 2025, 8:00 AM EDT - 7 weeks ago

Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

May 6, 2025, 8:00 AM EDT - 7 weeks ago

Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance

Apr 22, 2025, 8:00 AM EDT - 2 months ago

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Apr 17, 2025, 8:00 AM EDT - 2 months ago

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

Apr 15, 2025, 8:00 AM EDT - 2 months ago

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Apr 2, 2025, 8:00 AM EDT - 3 months ago

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo

Mar 28, 2025, 8:00 AM EDT - 3 months ago

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Mar 6, 2025, 9:00 PM EST - 4 months ago

Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:55 PM EST - 4 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Mar 4, 2025, 3:53 PM EST - 4 months ago

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Mar 4, 2025, 9:00 AM EST - 4 months ago

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Mar 4, 2025, 8:00 AM EST - 4 months ago

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Feb 28, 2025, 8:00 AM EST - 4 months ago

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Feb 27, 2025, 8:00 AM EST - 4 months ago

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Feb 19, 2025, 8:00 AM EST - 4 months ago

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Feb 18, 2025, 10:50 AM EST - 4 months ago

TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

ARDT

Feb 18, 2025, 8:00 AM EST - 4 months ago

Daxor to Exhibit at World's Largest Critical Care Conference

Feb 14, 2025, 8:00 AM EST - 4 months ago

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Feb 13, 2025, 8:00 AM EST - 4 months ago

New Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Dec 18, 2024, 8:00 AM EST - 6 months ago

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Oct 9, 2024, 8:00 AM EDT - 9 months ago

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Oct 8, 2024, 8:00 AM EDT - 9 months ago

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 5:00 PM EDT - 9 months ago

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Sep 19, 2024, 8:00 AM EDT - 10 months ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024

Sep 4, 2024, 8:30 AM EDT - 10 months ago

Leading Central Florida Hospital Implements Daxor's BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care

Sep 3, 2024, 4:05 PM EDT - 10 months ago

Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter

Sep 3, 2024, 12:15 PM EDT - 10 months ago

Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 8:00 AM EDT - 10 months ago

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network

Aug 5, 2024, 8:00 AM EDT - 11 months ago

Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

Mar 25, 2024, 8:05 PM EDT - 1 year ago

Daxor Corporation (DXR) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

Mar 18, 2024, 2:18 PM EDT - 1 year ago

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Mar 11, 2024, 8:00 AM EDT - 1 year ago

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base

Mar 8, 2024, 8:00 AM EST - 1 year ago

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor's Unique Clinical Utility for Heart Failure Patients

Feb 26, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions

Jan 2, 2024, 8:30 AM EST - 1 year ago

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Nov 13, 2023, 8:00 AM EST - 1 year ago

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure Patients

Oct 13, 2023, 8:00 AM EDT - 1 year ago

Expert Panelists Advocate Use of Daxor's Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific Meeting

Oct 11, 2023, 8:00 AM EDT - 1 year ago

New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023

Sep 11, 2023, 12:00 PM EDT - 1 year ago

Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

Sep 7, 2023, 9:15 AM EDT - 1 year ago

Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 28, 2023, 4:05 PM EDT - 1 year ago

Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023

akts Apr. 16 at 2:04 AM

0 · Reply

theshortsqueezer2022 Apr. 15 at 12:05 PM

0 · Reply

CEOBuysDisclosures Apr. 7 at 9:25 PM

$DXR CEO purchased 2,063 shares at $7.89 for a total of $16,277. Feldschuh Michael Richard now owns 212,694 shares. https://ceo-buys.com

0 · Reply

DonCorleone77 Mar. 28 at 12:09 PM

1 · Reply

NVDAMillionaire Mar. 22 at 6:57 PM

0 · Reply

CEOBuysDisclosures Mar. 20 at 11:15 PM

$DXR CEO purchased 1,492 shares at $7.72 for a total of $11,518. Feldschuh Michael Richard now owns 208,984 shares. https://ceo-buys.com

0 · Reply

CEOBuysDisclosures Mar. 20 at 11:10 PM

$DXR CEO purchased 647 shares at $8.15 for a total of $5,273. Feldschuh Michael Richard now owns 209,631 shares. https://ceo-buys.com

0 · Reply

JarvisFlow Mar. 17 at 11:00 AM

Ascendiant Capital has adjusted their stance on Daxor ( $DXR ), setting the rating to Buy with a target price of 24.75 → 25.

0 · Reply

CEOBuysDisclosures Mar. 11 at 3:40 PM

$DXR CEO purchased 3,360 shares at $7.68 for a total of $25,805. Feldschuh Michael Richard now owns 210,852 shares. https://ceo-buys.com

0 · Reply

topstockalerts Feb. 26 at 12:36 PM

Pre Market Top Gainers PT2 $HCTI $SMCX $AC $DXR $PRCH

0 · Reply

Doeyex Feb. 26 at 12:20 PM

$DXR

0 · Reply

BullMoonDude Feb. 3 at 9:44 AM

$RIME pump times $BHAT $DXR

0 · Reply

NVDAMillionaire Dec. 5 at 9:28 AM

$DXR Daxor Corporation (DXR): Pioneering the Future of Personalized Medicine through Innovative Blood Volume Diagnostics https://beyondspx.com/article/daxor-corporation-dxr-pioneering-the-future-of-personalized-medicine-through-innovative-blood-volume-diagnostics

0 · Reply

Stock_Titan Sep. 12 at 12:00 PM

$DXR Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management https://www.stocktitan.net/news/DXR/newly-published-review-highlights-the-pivotal-role-of-daxor-s-blood-fgi89kbn3ev2.html

0 · Reply

Stock_Titan Sep. 4 at 12:30 PM

$DXR Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care https://www.stocktitan.net/news/DXR/leading-central-florida-hospital-implements-daxor-s-bva-100-blood-lxdzqcxjs8yn.html

0 · Reply

Stock_Titan Sep. 3 at 8:05 PM

$DXR Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter https://www.stocktitan.net/news/DXR/daxor-corporation-ceo-and-president-michael-feldschuh-delivers-2ilo8uzpeq8l.html

0 · Reply

GambitMentality Aug. 30 at 8:11 PM

Today’s #StockMarket EOD Biggest Losers by %, led by $ESTC $ACAC and $DXR to lead the TOP 3

1 · Reply

GambitMentality Aug. 29 at 8:06 PM

Today’s #StockMarket EOD Biggest Gainers by %, led by $AFRM $SKIL and $DXR to lead the TOP 3

0 · Reply

LewisDaKat Aug. 29 at 7:55 PM

$DXR News Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network https://marketwirenews.com/news-releases/daxor-corporation-announces-launch-of-bva-program-at-4848829962805662.html $DXR

0 · Reply

Stock_Titan Aug. 29 at 12:00 PM

$DXR Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network https://www.stocktitan.net/news/DXR/daxor-corporation-announces-launch-of-bva-program-at-mid-south-uwf8c4i5c8zu.html

0 · Reply

akts Aug. 17 at 1:41 AM

$DXR turtles crawl faster than this company makes progress. Will it be 2026 or 2027 when we get DXR in gear?

0 · Reply

Stock_Titan Aug. 6 at 12:00 PM

$DXR Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer https://www.stocktitan.net/news/DXR/daxor-corporation-awarded-1-9m-contract-by-the-u-s-air-force-for-3myt6j6x197w.html

0 · Reply

Market Cap	45.42M
Revenue (ttm)	1.45M
Net Income (ttm)	-7.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-495.86%
Debt to Equity Ratio	0.00

Volume	4,725
Avg Vol	4,860
Day's Range	N/A - N/A
Shares Out	4.84M
Stochastic %K	90%
Beta	-0.13
Analysts	Strong Sell
Price Target	$23.50